<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172535</url>
  </required_header>
  <id_info>
    <org_study_id>P1083</org_study_id>
    <secondary_id>10787</secondary_id>
    <secondary_id>IMPAACT P1083</secondary_id>
    <nct_id>NCT01172535</nct_id>
    <nct_alias>NCT01338038</nct_alias>
  </id_info>
  <brief_title>A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines</brief_title>
  <official_title>A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of children and infants with HIV requires modification of medication dosing
      according to a child's specific weight. For lopinavir/ritonavir (LPV/r), a second line
      treatment option that is increasingly necessary due to infant drug resistance, this dosing is
      often complicated and impractical in busy clinical settings. To address this, the World
      Health Organization (WHO) has released a simplified dosing table based on infant weight
      bands. This study will evaluate the absorption, safety, and tolerance of LPV/r in infants
      when dosed according to the new WHO guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because of previous exposure to nevirapine or other non-nucleoside reverse transcriptase
      inhibitors (NNRTIs), either by direct treatment or through their mothers in pregnancy,
      infants must often receive an alternate antiretroviral regimen that includes LPV/r. Dosing of
      LPV/r is currently based on a child's specific weight, and calculations of proper dosages are
      often too complicated to be practical in busy clinics, particularly those in limited resource
      settings. In order to simplify medication delivery and reduce prescribing errors, the WHO has
      released a dosing schedule for LPV/r based on groupings of infants and children by weight.
      This study will evaluate the pharmacokinetics, safety, and tolerance of LPV/r dosed according
      to these guidelines. The following strata were used to guide accrual:

      Number of Participants to be Enrolled by Weight Band:

      3-4.9 kg: 11 liquid

      5-6.9 kg: 11 liquid

      7-9.9 kg: 17 liquid

      10-16.9 kg: 11 liquid, 22 tablet

      17-19.9 kg: 11 tablet

      20-24.9 kg: 11 tablet

      Participation in this study will last 6 months. Infant participants and their caretakers will
      need to attend study visits at entry and Weeks 2, 4, 12, and 24. At entry, participants will
      be given LPV/r either in liquid or tablet form, depending on whether they can swallow pills.
      Dosing will be calculated using the WHO schedule. At all study visits, participants will
      undergo a physical exam and caretakers will be asked about how well the child is taking the
      study medications. In addition, at Weeks 4, 12, and 24, blood samples will be taken from the
      participant to determine health and levels of the medication in the body. The visit on Week 4
      will also require pharmacokinetic testing, which means the child will need to be monitored at
      the hospital for 12 hours and complete six additional blood drawls. All other study visits
      will last 1 to 2 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)</measure>
    <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
    <description>Area under the curve over 24 hours (AUC0-24), as determined by a non-compartmental analysis of 12-hour pharmacokinetic sampling for lopinavir/ritonavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration of Lopinavir/Ritonavir (Cmax)</measure>
    <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
    <description>Maximum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration of Lopinavir/Ritonavir (Cmin)</measure>
    <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
    <description>Minimum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of Lopinavir/Ritonavir (CL/F)</measure>
    <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
    <description>Clearance of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants With an AUC of Less Than 10% of Adults</measure>
    <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
    <description>Proportion of participants with an AUC less that 10% of adults (AUC0-24 &lt;104 mcg*hr/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events of Grade 3 or 4</measure>
    <time_frame>Measured at study visits through end of study (weeks 2, 4, 12, 24)</time_frame>
    <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Tolerating LPV/r</measure>
    <time_frame>Measured at study completion (week 24)</time_frame>
    <description>Participants were considered to have tolerated medication if they did not stop treatment before the 24 week PK visit for any reason other than completing treatment or death not related to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Measured at week 4, week 12, and study completion (week 24)</time_frame>
    <description>Adherence, defined as proportion of doses taken (note: proportion could be greater than 1.0 for reasons such as tablets having to be taken twice due to first one being spit out or imprecise measurement of liquid doses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Efficacy (HIV Viral Load)</measure>
    <time_frame>Measured at entry and study completion (week 24)</time_frame>
    <description>Having HIV viral load &lt;400 copies/mL at the week 24 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Efficacy (CD4%)</measure>
    <time_frame>Measured at entry and study completion (week 24)</time_frame>
    <description>Having CD4%≥25 at the week 24 visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines</description>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>LPV/r</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight equal to or greater than 3 kg, but less than 25 kg, at the time of enrollment

          -  Confirmed diagnosis of HIV-1 infection

          -  Lopinavir/ritonavir (LPV/r)-treatment naïve and LPV/r-treatment eligible as defined by
             country-specific guidelines or the WHO pediatric treatment guidelines and confirmed by
             investigator

          -  Willingness to take two nucleoside reverse transcriptase inhibitos (NRTIs), in
             accordance with appropriate national or international treatment guidelines

          -  Demonstrated ability and willingness to swallow tablets for children larger than 10
             kg. This can be assessed before inclusion (for example, a test trial with similar size
             solid tablet such as tic-tac).

          -  Participants in the weight band between 10 and 16.9 kg that are unable to swallow
             tablets will receive liquid formulation

          -  Parent or legal guardian able and willing to provide written informed consent

        Exclusion Criteria:

          -  Planned concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTIs),
             integrase inhibitors, or an entry inhibitor

          -  Planned concurrent protease inhibitor (PI) use, other than LPV/r

          -  Prior treatment with LPV/r. Prior treatment with other PIs is allowed.

          -  Results of certain laboratory tests indicating adverse events of Grade 3 or greater

          -  Results of a lipase test indicating adverse event of Grade 2 or greater or clinical
             evidence of pancreatitis within 30 days prior to study entry

          -  Tuberculosis co-treatment with rifampicin-containing regimen

          -  Treatment with any enzyme-inducing antiepileptic drugs, such as henobarbital,
             phenytoin or carbamazepine

          -  Clinical condition requiring the use of a prohibited medication (see protocol for more
             details)

          -  Clinically unstable child requiring acute treatment for a serious opportunistic
             infection

          -  Chemotherapy for active malignancy

          -  Any clinically significant diseases (other than HIV-1 infection) or clinically
             significant findings during the screening medical history or physical examination
             that, in the investigator's opinion, would compromise participation in this study

          -  Treatment with experimental drugs for any indication within 30 days prior to study
             entry

          -  Known history of cardiac conduction abnormality and/or underlying structural heart
             disease, including congenital long QT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge A. Pinto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, UC San Diego CRS</name>
      <address>
        <city>La Jolla,</city>
        <state>California</state>
        <zip>92093-0672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Ped. HIV Program NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOM Federal University Minas Gerais Brazil NICHD CRS</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Santa Casa Porto Alegre Brazil NICHD CRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Federal dos Servidores do Estado NICHD CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-612</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Geral De Nova Igaucu Brazil NICHD CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>26030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Sao Paulo Brazil NICHD CRS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandukani CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit (FAM-CRU) CRS</name>
      <address>
        <city>Tygerberg</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University CRS</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkoknoi</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hosp. CRS</name>
      <address>
        <city>Saimai</city>
        <state>Bangkok</state>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hosp. CRS</name>
      <address>
        <city>Chantaburi</city>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital CRS</name>
      <address>
        <city>Chiangrai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hosp. CRS</name>
      <address>
        <city>Chonburi</city>
        <zip>2000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao Provincial Hosp. CRS</name>
      <address>
        <city>Phayao</city>
        <zip>56000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>November 16, 2015</results_first_submitted>
  <results_first_submitted_qc>November 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2015</results_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lopinavir/ritonavir</keyword>
  <keyword>Pediatric dosing</keyword>
  <keyword>World Health Organization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 97 participants enrolled from 19 clinical sites in four countries. There were 57 participants on the liquid formulation and 40 on tablet. Accrual took place from May 20, 2011 through June 19, 2013.</recruitment_details>
      <pre_assignment_details>HIV-infected infants and children ≥3 to &lt;25 kg had to be LPV/r-treatment naïve. Children ≥10 kg had to demonstrate ability and willingness to swallow tablets. Participants were stratified by weight and drug formulation (liquid vs. tablet).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lopinavir/Ritonavir</title>
          <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible at study entry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unwilling to adhere to study requirement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Lopinavir/Ritonavir</title>
          <description>Participants receiving lopinavir/ritonavirr, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="0.5" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA (copies/mL) at study entry</title>
          <units>log copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" lower_limit="4.6" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4% at study entry</title>
          <units>percentage of total lymphocytes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.2" lower_limit="15.8" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)</title>
        <description>Area under the curve over 24 hours (AUC0-24), as determined by a non-compartmental analysis of 12-hour pharmacokinetic sampling for lopinavir/ritonavir</description>
        <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
        <population>Participants having complete pharmacokinetics data at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)</title>
          <description>Area under the curve over 24 hours (AUC0-24), as determined by a non-compartmental analysis of 12-hour pharmacokinetic sampling for lopinavir/ritonavir</description>
          <population>Participants having complete pharmacokinetics data at week 4</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="177" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration of Lopinavir/Ritonavir (Cmax)</title>
        <description>Maximum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
        <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
        <population>Participants having complete pharmacokinetics data at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration of Lopinavir/Ritonavir (Cmax)</title>
          <description>Maximum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
          <population>Participants having complete pharmacokinetics data at week 4</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" lower_limit="10.24" upper_limit="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration of Lopinavir/Ritonavir (Cmin)</title>
        <description>Minimum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
        <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
        <population>Participants having complete pharmacokinetics data at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration of Lopinavir/Ritonavir (Cmin)</title>
          <description>Minimum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
          <population>Participants having complete pharmacokinetics data at week 4</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" lower_limit="1.52" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance of Lopinavir/Ritonavir (CL/F)</title>
        <description>Clearance of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
        <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
        <population>Participants having complete pharmacokinetics data at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Lopinavir/Ritonavir (CL/F)</title>
          <description>Clearance of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling</description>
          <population>Participants having complete pharmacokinetics data at week 4</population>
          <units>L/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.13" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With an AUC of Less Than 10% of Adults</title>
        <description>Proportion of participants with an AUC less that 10% of adults (AUC0-24 &lt;104 mcg*hr/mL)</description>
        <time_frame>Measured at 4 weeks of treatment prior to the observed dose and at 2, 4, 6, 8, and 12 hours post-dose</time_frame>
        <population>Participants with complete pharmacokinetics data at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With an AUC of Less Than 10% of Adults</title>
          <description>Proportion of participants with an AUC less that 10% of adults (AUC0-24 &lt;104 mcg*hr/mL)</description>
          <population>Participants with complete pharmacokinetics data at week 4</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.09" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence</title>
        <description>Adherence, defined as proportion of doses taken (note: proportion could be greater than 1.0 for reasons such as tablets having to be taken twice due to first one being spit out or imprecise measurement of liquid doses)</description>
        <time_frame>Measured at week 4, week 12, and study completion (week 24)</time_frame>
        <population>Participants bringing medication to be measured at the study visit</population>
        <group_list>
          <group group_id="O1">
            <title>Week 4</title>
            <description>Participants bringing medication to be measured at study week 4</description>
          </group>
          <group group_id="O2">
            <title>Week 12</title>
            <description>Participants bringing medication to be measured at study week 12</description>
          </group>
          <group group_id="O3">
            <title>Week 24</title>
            <description>Participants bringing medication to be measured at study week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>Adherence, defined as proportion of doses taken (note: proportion could be greater than 1.0 for reasons such as tablets having to be taken twice due to first one being spit out or imprecise measurement of liquid doses)</description>
          <population>Participants bringing medication to be measured at the study visit</population>
          <units>Proportion of expected doses taken</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.97" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.88" upper_limit="1.01"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.91" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Efficacy (HIV Viral Load)</title>
        <description>Having HIV viral load &lt;400 copies/mL at the week 24 visit</description>
        <time_frame>Measured at entry and study completion (week 24)</time_frame>
        <population>Participants with data from both study entry and the week 24 study visit</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy (HIV Viral Load)</title>
          <description>Having HIV viral load &lt;400 copies/mL at the week 24 visit</description>
          <population>Participants with data from both study entry and the week 24 study visit</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.61" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Efficacy (CD4%)</title>
        <description>Having CD4%≥25 at the week 24 visit.</description>
        <time_frame>Measured at entry and study completion (week 24)</time_frame>
        <population>Participants with data from both study entry and the week 24 study visit</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy (CD4%)</title>
          <description>Having CD4%≥25 at the week 24 visit.</description>
          <population>Participants with data from both study entry and the week 24 study visit</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.60" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events of Grade 3 or 4</title>
        <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death</description>
        <time_frame>Measured at study visits through end of study (weeks 2, 4, 12, 24)</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events of Grade 3 or 4</title>
          <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants Tolerating LPV/r</title>
        <description>Participants were considered to have tolerated medication if they did not stop treatment before the 24 week PK visit for any reason other than completing treatment or death not related to treatment.</description>
        <time_frame>Measured at study completion (week 24)</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Tolerating LPV/r</title>
          <description>Participants were considered to have tolerated medication if they did not stop treatment before the 24 week PK visit for any reason other than completing treatment or death not related to treatment.</description>
          <population>All participants</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.86" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From entry until off-study (week 24)</time_frame>
      <desc>Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included Aes resulting in death, significant disabilities, requiring hospitalization, and ≥grade 3 Aes defined by the “DAIDS Table for Grading the Severity of Adult and Pediatric Aes”, V1.0, 12/2004.</desc>
      <group_list>
        <group group_id="E1">
          <title>LPV/r</title>
          <description>Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome associated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival pallor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Amylase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Use of accessory respiratory muscles</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and seven (7) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

